

includes whether the acquisition of the nonbanking company complies with the standards in section 10(c)(4)(B) of the HOLA (12 U.S.C. 1467a(c)(4)(B)). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 24, 2017.

A. *Federal Reserve Bank of Cleveland* (Nadine Wallman, Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101–2566. Comments can also be sent electronically to

[Comments.applications@clev.frb.org](mailto:Comments.applications@clev.frb.org).

1. *Eagle Financial Bancorp, Inc.*, Cincinnati, Ohio; to become a savings and loan holding company by acquiring Eagle Savings Bank, Cincinnati, Ohio, in connection with the mutual-to-stock conversion of Eagle Savings Bank.

Board of Governors of the Federal Reserve System, March 24, 2017.

**Robert deV. Frierson,**

*Secretary of the Board.*

[FR Doc. 2017–06197 Filed 3–28–17; 8:45 am]

**BILLING CODE 6210–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Document Identifier: 4040–0018; 30-day Notice]

### Agency Information Collection Request; 30-Day Public Comment Request, Grants.gov

**AGENCY:** Office of the Secretary, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, *Grants.gov* (EGOV), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, email your request, including your address, phone number, OMB number, to [Ed.Calimaga@hhs.gov](mailto:Ed.Calimaga@hhs.gov), or call the Reports Clearance Office on (202) 690–7569. Send written comments and recommendations for the proposed information collections within 30 days of this notice directly to the *Grants.gov*.

#### *Proposed Project:*

SF–428 Tangible Personal Property Report.

Reinstatement without change and 3 Year Extension and assignment as a Common Form.

OMB No.: 4040–0018.

Office: *Grants.gov*.

**Abstract:** Reporting on the status of Federally owned property, including disposition, is necessitated in 2 CFR part 215, the “Uniform Administrative Requirements for Grants and Agreements with Institutions of Higher Education, Hospitals, and Other Non-Profit Organizations”, and the “Uniform Administrative Requirements for Grants and Agreements with State and Local Governments”, Additionally, Public Law 106–107, the Federal Financial Assistance Management Improvement Act requires that agencies “simplify Federal financial assistance application and reporting requirements.” 31 U.S.C. 6101, Section 3.

Agencies are currently using a variety of forms to account for both Federally owned and grantee owned equipment and property. During the public consultation process mandated by Public Law 106–107, grant recipients requested a standard form to help them submit appropriate property information when required. The Public Law 106–107 Post Awards Subgroup developed a new standard form, the Tangible Personal Property Report, for submission of the required data. The form consists of the cover sheet (SF–428), three attachments to be used as required: Annual Report, SF–428–A; Final Report, SF–428–B; Disposition Request/Report, SF–428–C and a Supplemental Sheet, SF–428S to provide detailed individual item information when required. We are requesting a three-year clearance of this collection and that it be designated as a Common Form.

### TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden hours
SF–428 Tangible Personal Property Report .....	2000	1	1	2000
Total .....	2000	.....	.....	2000

**Terry S. Clark,**

*Asst. Information Collection Clearance Officer.*

[FR Doc. 2017–06142 Filed 3–28–17; 8:45 am]

**BILLING CODE 4151–AE–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel; Imaging and Biomarkers for Early Detection of Aggressive Cancer.

Date: April 21, 2017.

Time: 9:30 a.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892,

Contact Person: Xiang-Ning Li, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5112, MSC 7854, Bethesda, MD 20892, 301-435-1744, [lixiang@csr.nih.gov](mailto:lixiang@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 23, 2017.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017-06147 Filed 3-28-17; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Request for Information for the Development of the Fiscal Year 2019 Trans-NIH Plan for HIV-Related Research

**SUMMARY:** Through this Request for Information (RFI), the Office of AIDS Research (OAR) in the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), National Institutes of Health (NIH), invites feedback from investigators in academia, industry, health care professionals, patient advocates and health advocacy organizations, scientific or professional organizations, federal agencies, community, and other interested constituents on the development of the fiscal year (FY) 2019 Trans-NIH Plan for HIV-Related Research (FY 2019 AIDS Research Plan). This plan is designed to identify and articulate future directions to maximize the NIH's investments in HIV/AIDS research.

**DATES:** The OAR's Request for Information is open for public comment for a period of 45 days. Comments must be received by May 15, 2017 to ensure consideration. After the public comment period has closed, the comments received by the OAR will be considered in a timely manner for the development of the FY2019 AIDS Research Plan.

**ADDRESSES:** Submissions may be electronically sent to <http://grants.nih.gov/grants/rfi/rfi.cfm?ID=63> or, if needed, by mail to Paul Gaist, Ph.D., M.P.H. Office of AIDS Research,

National Institutes of Health, Room 2E40, 5601 Fishers Lane, Rockville, Maryland 20852.

#### FOR FURTHER INFORMATION CONTACT:

Questions about this request for information should be directed to Paul Gaist, Ph.D., M.P.H. Office of AIDS Research, National Institutes of Health Email: [ODOARRFI19@nih.gov](mailto:ODOARRFI19@nih.gov) or if needed, by mail to Room 2E40, 5601 Fishers Lane, Rockville, Maryland 20852.

**SUPPLEMENTARY INFORMATION:** To access and respond to the RFI, go to the following Web address: <http://grants.nih.gov/grants/rfi/rfi.cfm?ID=63>.

OAR oversees and coordinates the conduct and support of all HIV/AIDS research activities across the NIH Institutes and Centers (ICs). The NIH-sponsored HIV/AIDS research program includes both extramural and intramural research, buildings and facilities, research training, program evaluation, and supports a comprehensive portfolio of research representing a broad range of basic, clinical, behavioral, social science, and translational research on HIV/AIDS and its associated coinfections and comorbidities.

OAR plans and coordinates research through the development of an annual Trans-NIH Plan for HIV-Related Research that articulates the overarching HIV/AIDS research priorities and serves as the framework for developing the trans-NIH HIV/AIDS research budget. This Plan provides information about the NIH's HIV/AIDS research priorities to the scientific community, Congress, community stakeholders, HIV-affected communities, and the broad public at large. The fiscal year 2018 Trans-NIH Plan for HIV-Related Research was recently distributed on the OAR Web site: ([https://www.oar.nih.gov/strategic\\_plan/plan\\_18.asp](https://www.oar.nih.gov/strategic_plan/plan_18.asp)).

New overarching priorities for HIV/AIDS research were defined in the NIH Director's Statement of August 12, 2015 (<https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html>).

High Priority topics of research for support include:

- (1) Reducing the incidence of HIV/AIDS;
- (2) Developing the next generation of HIV therapies;
- (3) Identifying strategies towards a cure;
- (4) Improving the prevention and treatment of HIV-associated comorbidities, coinfections, and complications; and
- (5) Cross-cutting basic research, behavioral and social science research, health disparities, and training.

This RFI is for planning purposes only and should not be construed as a solicitation for applications or proposals, or as an obligation in any way on the part of the United States federal government. The federal government will not pay for the preparation of any information submitted or for the government's use. Additionally, the government cannot guarantee the confidentiality of the information provided.

Dated: March 23, 2017.

Lawrence A. Tabak,

Deputy Director, National Institutes of Health.

[FR Doc. 2017-06183 Filed 3-28-17; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Advancing Translational Sciences; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of meetings of the National Center for Advancing Translational Sciences.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Cures Acceleration Network Review Board.

Date: May 4, 2017.

Time: 8:30 a.m. to 2:30 p.m.

Agenda: Report from the Institute Director.

Place: National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

Contact Person: Anna L. Ramsey-Ewing, Ph.D., Executive Secretary, National Center for Advancing Translational Sciences, 1 Democracy Plaza, Room 1072, Bethesda, MD 20892, 301-435-0809, [anna.ramseyewing@nih.gov](mailto:anna.ramseyewing@nih.gov).